The second batch of Commissioner's national priority vouchers (CNPVs) has been published by the FDA, and includes new GLP-1 agonists for weight-loss from Eli Lilly and Novo Nordisk and drugs for ...
HES can provide the kind of real-world evidence that some life sciences companies have a great deal of difficulty in ...
According to the White House, Novo Nordisk's semaglutide-based Ozempic for diabetes and Wegovy for obesity will cost $350 per ...
The US regulator has cleared Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major ...
Eli Lilly has raised the stakes in the obesity market with midstage data for an amylin-targeting drug, eloralintide, that ...
The new data from the OASIS 4 trial of Novo Nordisk's 25 mg oral formulation of semaglutide included an indirect comparison ...
AZ has already made it clear its focus is on investing in the US market – which accounts for 30% of its sales – and started ...
Although rare kidney diseases remain a significantly overlooked contributor to the global burden of CKD, things have begun to ...
Pfizer – which first agreed a $4.9 billion takeover deal with Metsera in September – has argued that the rival bid is ...
That research led to the FDA granting compassionate use of the doxecitine and doxribtimine treatment in Arturito Estopinan, ...
Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, causing shares in the ...
The merger of two pioneers of psychedelic medicines has completed with the creation of AtaiBeckley, a company with a pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback